Cargando…

Activation of Tyrosine Metabolism in CD13(+) Cancer Stem Cells Drives Relapse in Hepatocellular Carcinoma

PURPOSE: Cancer stem cells (CSCs) are naturally resistant to chemotherapy, explaining why tumor relapse frequently occurs after initial regression upon administration of chemotherapeutic agents in most cases. A CSC population characterized by CD13 expression has been identified in hepatocellular car...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Li, Zhang, Lin, Chen, Jun, Li, Chaoqun, Sun, Hongqin, Wang, Jiangrong, Xiao, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176959/ https://www.ncbi.nlm.nih.gov/pubmed/32019286 http://dx.doi.org/10.4143/crt.2019.444

Ejemplares similares

SETD1A drives stemness by reprogramming the epigenetic landscape in hepatocellular carcinoma stem cells
por: Chen, Jianxu, et al.
Publicado: (2023)

The predictive value of centre tumour CD8(+) T cells in patients with hepatocellular carcinoma: comparison with Immunoscore
por: Sun, Cheng, et al.
Publicado: (2015)

TLR4 increases the stemness and is highly expressed in relapsed human hepatocellular carcinoma
por: Zhou, Shuang, et al.
Publicado: (2019)

Suppression of CD13 Enhances the Cytotoxic Effect of Chemotherapeutic Drugs in Hepatocellular Carcinoma Cells
por: Ji, Shengping, et al.
Publicado: (2021)

Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma
por: Hung, Man Hsin, et al.
Publicado: (2021)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
por: Yang, Fei, et al.
Publicado: (2022)

CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia
por: Farge, Thomas, et al.
Publicado: (2023)

Development and Validation of a Propionate Metabolism-Related Gene Signature for Prognostic Prediction of Hepatocellular Carcinoma
por: Xiao, Jincheng, et al.
Publicado: (2023)

SNRPB-mediated RNA splicing drives tumor cell proliferation and stemness in hepatocellular carcinoma
por: Zhan, Yu-Ting, et al.
Publicado: (2020)

The Roles of Protein Tyrosine Phosphatases in Hepatocellular Carcinoma
por: Huang, Yide, et al.
Publicado: (2018)

Ecology Drives the Distribution of Specialized Tyrosine Metabolism Modules in Fungi
por: Greene, George H., et al.
Publicado: (2014)

Decreased SLC27A5 Suppresses Lipid Synthesis and Tyrosine Metabolism to Activate the Cell Cycle in Hepatocellular Carcinoma
por: Wang, Jiyan, et al.
Publicado: (2022)

PGK1 Drives Hepatocellular Carcinoma Metastasis by Enhancing Metabolic Process
por: Xie, Huijun, et al.
Publicado: (2017)

Roles of protein tyrosine phosphatases in hepatocellular carcinoma progression (Review)
por: Chen, Yi-Li, et al.
Publicado: (2023)

Amplification of USP13 drives ovarian cancer metabolism
por: Han, Cecil, et al.
Publicado: (2016)

Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44+ cancer stem cells to 5 azacytidine in hepatocellular carcinoma
por: Gao, Xiaomei, et al.
Publicado: (2018)

Cancer stem cells of hepatocellular carcinoma
por: Wang, Kewei, et al.
Publicado: (2018)

Overexpressed Histocompatibility Minor 13 was Associated with Liver Hepatocellular Carcinoma Progression and Prognosis
por: Zong, Rui-Qing, et al.
Publicado: (2022)

Correction: Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44 + cancer stem cells to 5 azacytidine in hepatocellular carcinoma
por: Gao, Xiaomei, et al.
Publicado: (2023)

Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response
por: Yang, Fei, et al.
Publicado: (2022)

Identification and validation of a tyrosine metabolism-related prognostic prediction model and characterization of the tumor microenvironment infiltration in hepatocellular carcinoma
por: Zhou, Yangying, et al.
Publicado: (2022)

The Role of Proline Rich Tyrosine Kinase 2 (Pyk2) on Cisplatin Resistance in Hepatocellular Carcinoma
por: Geng, Wei, et al.
Publicado: (2011)

Diabetes Mellitus is a Risk Factor for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection in China
por: Li, Xu, et al.
Publicado: (2018)

The significance of proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrence
por: Sun, C K, et al.
Publicado: (2007)

Oncogenic function and prognostic significance of protein tyrosine phosphatase PRL-1 in hepatocellular carcinoma
por: Jin, Shaowen, et al.
Publicado: (2014)

Clinicopathological Features of Hepatocellular Carcinoma with Metabolic Risk Factors
por: Sun, Lei, et al.
Publicado: (2023)

Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma
por: Liang, Linjun, et al.
Publicado: (2023)

Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world
por: Xie, Diyang, et al.
Publicado: (2021)

MUC13 Interaction with Receptor Tyrosine Kinase HER2 Drives Pancreatic Ductal Adenocarcinoma Progression
por: Khan, Sheema, et al.
Publicado: (2016)

The Clinical Significance of the CD163+ and CD68+ Macrophages in Patients with Hepatocellular Carcinoma
por: Kong, Ling-Qun, et al.
Publicado: (2013)

A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma
por: YAMASHITA, MASAFUMI, et al.
Publicado: (2016)

Association between ABO blood group and HCV-related hepatocellular carcinoma risk in China
por: Li, Xu, et al.
Publicado: (2016)

CD73 sustained cancer-stem-cell traits by promoting SOX9 expression and stability in hepatocellular carcinoma
por: Ma, Xiao-Lu, et al.
Publicado: (2020)

PD-1(+)CXCR5(−)CD4(+) Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma
por: Li, Jiang-Ping, et al.
Publicado: (2021)

Mitochondrial Fuel Dependence on Glutamine Drives Chemo-Resistance in the Cancer Stem Cells of Hepatocellular Carcinoma
por: Lee, Alan Chun Kit, et al.
Publicado: (2021)

Chromenopyrimidinone Controls Stemness and Malignancy by suppressing CD133 Expression in Hepatocellular Carcinoma
por: Song, Yeonhwa, et al.
Publicado: (2020)

CLIC1 Drives Angiogenesis in Hepatocellular Carcinoma by Modulating VEGFA
por: Wei, Xuyong, et al.
Publicado: (2022)

MFN1-dependent alteration of mitochondrial dynamics drives hepatocellular carcinoma metastasis by glucose metabolic reprogramming
por: Zhang, Ze, et al.
Publicado: (2019)

The Notch pathway promotes the cancer stem cell characteristics of CD90(+) cells in hepatocellular carcinoma
por: Luo, Jing, et al.
Publicado: (2015)

An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma
por: Sun, Hanyong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_43322e386m1cdmokd390s7afgn